Prognostic Value of Regadenoson Stress Perfusion CMR
Medical Sciences · 10.04.2026 · 14 (2) · 190
DOI: 10.3390/medsci14020190 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Sciences, online erschienen am 10.04.2026. Verfasst von Javier Muñiz-Sáenz-Diez und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Clínica Universidad de Navarra, 31008 Pamplona, Spain. Hauptthemen laut MEDLINE: Purines, Pyrazoles, Myocardial Ischemia. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Regadenoson is increasingly used as a vasodilator stress agent for perfusion cardiac magnetic resonance (CMR) imaging due to its favorable pharmacologic profile. However, its long-term prognostic value in patients with myocardial ischemia remains insufficiently established.
Methods
We retrospectively analyzed all regadenoson stress-CMR studies performed at our institution between May 2017 and July 2020, including patients with follow-up longer than three months. Inducible ischemia and late gadolinium enhancement (LGE) were assessed using standardized criteria. The primary composite endpoint included cardiovascular death, non-fatal myocardial infarction, late coronary revascularization (≥3 months after CMR), or hospitalization for unstable angina. Event-free survival was analyzed with Kaplan–Meier curves, and prognostic factors were evaluated using a Fine–Gray competing-risks model.
Results
Of 705 examinations, 698 were eligible, and 517 patients (78.5%) completed follow-up over a median of 1.93 years (IQR 1.37–2.79). Inducible ischemia was identified in 142 patients (27.5%). During follow-up, 38 composite events occurred. Event incidence was significantly higher in patients with ischemia (109.6 events/1000 person-years; 95% CI 75.7–158.7) than in those without (13.3 events/1000 person-years; 95% CI 7.2–24.7; RR 8.25; 95% CI 4.01–16.98; p < 0.001). In multivariable analysis, inducible ischemia independently predicted adverse outcomes (HR 4.50; 95% CI 1.86–10.9; p = 0.001), whereas LGE was not independently associated (HR 1.28; 95% CI 0.46–3.57; p = 0.63).
Conclusions
Regadenoson stress-CMR provides robust medium-term risk stratification in patients with suspected or known coronary artery disease. Detection of inducible ischemia strongly predicts major cardiovascular events, underscoring its prognostic and clinical relevance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
- Department of Radiology, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
- Department of Radiology, Clínica Universidad de Navarra, 28027 Madrid, Spain.
- Department of Cardiology, Clínica Universidad de Navarra, 28027 Madrid, Spain.
ORCID-Profile: Ana Ezponda, Nahikari Salterain, Gorka Bastarrika
Zitieren
APA
Muñiz-Sáenz-Diez, J., Ezponda, A., Caballeros, M., de la Fuente, A., Salterain, N., & Bastarrika, G. (2026). Prognostic Value of Regadenoson Stress Perfusion CMR. Medical Sciences, 14(2), 190. https://doi.org/10.3390/medsci14020190
Vancouver
Muñiz-Sáenz-Diez J, Ezponda A, Caballeros M, de la Fuente A, Salterain N, Bastarrika G. Prognostic Value of Regadenoson Stress Perfusion CMR. Medical Sciences. 2026;14(2):190. doi:10.3390/medsci14020190
BibTeX
@article{MuizSenzDiez2026,
author = {Muñiz-Sáenz-Diez, Javier and Ezponda, Ana and Caballeros, Meylin and de la Fuente, Ana and Salterain, Nahikari and Bastarrika, Gorka},
title = {Prognostic Value of Regadenoson Stress Perfusion CMR},
journal = {Medical Sciences},
year = {2026},
volume = {14},
number = {2},
pages = {190},
doi = {10.3390/medsci14020190}
}
EUVIMED